Literature DB >> 18782856

Switching anti-TNF therapy in ankylosing spondylitis.

D J Pradeep, A C Keat, K Gaffney, A Brooksby, J Leeder, C Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18782856     DOI： 10.1093/rheumatology/ken334

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  12 in total

Review 1.  Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.

Authors:  Valeria Rios Rodriguez; Denis Poddubnyy
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-05-09       Impact factor: 5.346

2.  Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.

Authors:  Guenther Haberhauer; Christoph Strehblow; Peter Fasching
Journal:  Wien Med Wochenschr       Date:  2010-05

3.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Authors:  Martin Rudwaleit; Filip Van den Bosch; Martina Kron; Sonja Kary; Hartmut Kupper
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

4.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

Review 5.  Spondyloarthritides: evolving therapies.

Authors:  Andrew Barr; Andrew Keat
Journal:  Arthritis Res Ther       Date:  2010-12-17       Impact factor: 5.156

6.  Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.

Authors:  Marta Fabbroni; Luca Cantarini; Francesco Caso; Luisa Costa; Veronica Anna Pagano; Bruno Frediani; Stefania Manganelli; Mauro Galeazzi
Journal:  Mediators Inflamm       Date:  2014-07-08       Impact factor: 4.711

7.  Anti-IL17A in Axial Spondyloarthritis-Where Are We At?

Authors:  Peter P Cheung
Journal:  Front Med (Lausanne)       Date:  2017-01-18

8.  Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician.

Authors:  Laura C Coates; Helena Marzo-Ortega; Alexander N Bennett; Paul Emery
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

9.  Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.

Authors:  Adrian Ciurea; Pascale Exer; Ulrich Weber; Giorgio Tamborrini; Beate Steininger; Rudolf O Kissling; Jürg Bernhard; Almut Scherer
Journal:  Arthritis Res Ther       Date:  2016-03-22       Impact factor: 5.156

10.  Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice.

Authors:  Tamara Rusman; Saskia Ten Wolde; Sjoerd M Euser; Tjeerd van der Ploeg; Odile van Hall; Irene E van der Horst-Bruinsma
Journal:  Int J Rheum Dis       Date:  2018-04       Impact factor: 2.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.